NEW DELHI: Poor sales of respiratory and anti-infectives due to waning winter pulled down domestic pharma retail market in March to a flat growth of 1.3% year-on-year. Typically, asthma and respiratory diseases abound during winter months, further complicated by the toxic air.
The poor showing comes on the back of the market posting a robust growth in the preceding months — 8% in Feb and nearly 20% in Jan, data culled from market research firm IQVIA said.Among top rankers, Foracort, used for asthma and respiratory issues, assumed the top slot in the market with a 10% growth year-on-year in March, netting Rs 73 crore sales. It was followed by popular antibiotic, Antibiotic and anti-diabetic Glycomet-GP, with sales of Rs 68 crore and Rs 66 crore, respectively during the month. Amont the top 10 brands, Udiliv — used for liver-related disorders — recorded highest growth of 23% during the month.
The market was impacted by a sharp decline of 8% and 7% in respiratory and anti-infective therapies. Cardiac, followed by dermatology, posted 8% and 6% growth and were among top-10 growing therapies in the Rs 17,500 crore market. Respiratory therapies, including anti-asthma drugs, had registered a 20% growth in Feb — ironically pointing to our struggle with the growing pollution levels during the winter months.
For five consecutive months, chronic therapy has outperformed acute therapy.
The poor showing comes on the back of the market posting a robust growth in the preceding months — 8% in Feb and nearly 20% in Jan, data culled from market research firm IQVIA said.Among top rankers, Foracort, used for asthma and respiratory issues, assumed the top slot in the market with a 10% growth year-on-year in March, netting Rs 73 crore sales. It was followed by popular antibiotic, Antibiotic and anti-diabetic Glycomet-GP, with sales of Rs 68 crore and Rs 66 crore, respectively during the month. Amont the top 10 brands, Udiliv — used for liver-related disorders — recorded highest growth of 23% during the month.
The market was impacted by a sharp decline of 8% and 7% in respiratory and anti-infective therapies. Cardiac, followed by dermatology, posted 8% and 6% growth and were among top-10 growing therapies in the Rs 17,500 crore market. Respiratory therapies, including anti-asthma drugs, had registered a 20% growth in Feb — ironically pointing to our struggle with the growing pollution levels during the winter months.
For five consecutive months, chronic therapy has outperformed acute therapy.